Leo Pharma Enters Partnership to Develop Topical Treatment for Rare Skin Cancer
The Danish company Leo Pharma and the US biotech PellePharm have joined forces to develop…
The Danish company Leo Pharma and the US biotech PellePharm have joined forces to develop…
Though the psoriasis market is teeming with effective products, companies have developed ways to devise…
Update (20/07/2017): The European Commision has granted LEO Pharma marketing authorization for Kyntheum (brodalumab), making it…
argenx's 2015 deal with Leo Pharma for anti-inflammatory antibodies continues to pay off, though it hasn't…
Leo Pharma is offering MorphoSys no less than €111.5M per antibody treatment with applications in…
New results from a Phase III trial show that guselkumab, an antibody therapy for the autoimmune…
Leo Pharma is acquiring rights to two of AstraZeneca's candidates. The targeted indications are atopic…
ArGEN-X in Ghent (Belgium) combines the diversity of the llama immune system with a clinical antibody…
Which part of our body do European biotechs prefer to target? And how diversified are…